Low molecular weight heparin buccal spray - Generex Biotechnology Corporation

Drug Profile

Low molecular weight heparin buccal spray - Generex Biotechnology Corporation

Alternative Names: LMW heparin buccal spray; Low molecular weight heparin oral spray

Latest Information Update: 15 Jan 2013

Price : $50

At a glance

  • Originator Generex Biotechnology Corporation
  • Class Antithrombotics; Low molecular weight heparins
  • Mechanism of Action Antithrombin III stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Deep vein thrombosis

Most Recent Events

  • 01 Jan 2013 Low molecular weight heparin buccal spray is available for licensing as of 01 Jan 2013. \(http://www.generex.com/\)
  • 31 May 2004 No development reported - Phase-I for Deep vein thrombosis in Canada (Buccal)
  • 14 May 2002 Phase-I clinical trials in Deep vein thrombosis in Canada (Buccal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top